Terapias no farmacológicas en el tratamiento de Alzheimer
Archivos
NO SE HA AUTORIZADO la consulta de los documentos asociados
Fecha
2022-03-31
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Resumen
Según los datos de la Sociedad Española de Neurologia actualmente hay unos 800.000 casos de Alzheimer en nuestro país, convirtiéndose este en el tipo de demencia neurodegenerativa más común. Con estos datos España se convierte en uno de los países del mundo con mayor proporción de casos de Alzheimer, además, como consecuencia del envejecimiento de la sociedad española, en los próximos 20 años se espera que la prevalencia de la enfermedad sea el doble.
Aunque los fármacos enlentecen el avance de la enfermedad por sí mismos, en muchos casos, se necesitará algo mas para favorecer que los pacientes tengan una vida plena. Las terapias no farmacológicas pueden mejorar la calidad de vida de los afectados, además de tener un coste inferior.
According to data from the Spanish Society of Neurology, there are currently about 800,000 cases of Alzheimer's in our country, making this the most common type of neurodegenerative dementia. With these data, Spain becomes one of the countries in the world with the highest proportion of Alzheimer's cases, in addition, as a consequence of the aging of Spanish society, in the next 20 years the prevalence of the disease is expected to double. Although drugs themselves slow the progression of the disease, in many cases, more will be needed to help patients lead a full life. Non-pharmacological therapies can improve the quality of life of those affected, in addition to having a lower cost.
According to data from the Spanish Society of Neurology, there are currently about 800,000 cases of Alzheimer's in our country, making this the most common type of neurodegenerative dementia. With these data, Spain becomes one of the countries in the world with the highest proportion of Alzheimer's cases, in addition, as a consequence of the aging of Spanish society, in the next 20 years the prevalence of the disease is expected to double. Although drugs themselves slow the progression of the disease, in many cases, more will be needed to help patients lead a full life. Non-pharmacological therapies can improve the quality of life of those affected, in addition to having a lower cost.